Skip to content
NeuroDerm
Continuous Therapy
NeuroDerm
  • Home
  • NeuroDerm
    • About NeuroDerm
    • Management and Key Employees
    • Board
    • Scientific Advisory Board
  • Parkinson’s Disease
    • PD Overview
    • Resources
  • Pipeline Products
    • Overview
    • ND0612L for moderate PD
    • ND0612H for severe PD
    • ND0701 for severe PD
    • Scientific Publications
  • Clinical trials
    • What is ND0612 ?
    • ND0612 ongoing clinical trials
    • Risks related to ND0612 clinical studies
  • Contact
  • Home
  • NeuroDerm
    • About NeuroDerm
    • Management and Key Employees
    • Board
    • Scientific Advisory Board
  • Parkinson’s Disease
    • PD Overview
    • Resources
  • Pipeline Products
    • Overview
    • ND0612L for moderate PD
    • ND0612H for severe PD
    • ND0701 for severe PD
    • Scientific Publications
  • Clinical trials
    • What is ND0612 ?
    • ND0612 ongoing clinical trials
    • Risks related to ND0612 clinical studies
  • Contact

Daily Archives: July 9, 2014

You are here:
  1. Home
  2. 2014
  3. July
  4. 09

NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612L, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease

Press ReleasesBy Foothold SystemsJuly 9, 2014

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.

NeuroDerm
Copyright NeuroDerm © 2014 All rights reserved.
Go to Top